Methods to increase the percentage of free fetal DNA recovered from the maternal circulation.
BACKGROUND
Noninvasive prenatal diagnostic tests using free fetal DNA provide an alternative to invasive tests and their attendant risks; however, free fetal DNA exists in the maternal circulation at low percentages, which has hindered development of noninvasive tests.


OBJECTIVE
To test the hypothesis that using formaldehyde to reduce cell lysis could increase the relative percentage of free fetal DNA in samples of maternal blood.


METHODS
The first phase of the study was conducted from January through February 2002 at a single US clinical site; 2 samples of blood were collected from each of 10 pregnant women, and the percentage of free fetal DNA in formaldehyde-treated and untreated samples was determined. The second phase of the study was conducted from March 2002 through May 2003, and measured the percentage of free fetal DNA in 69 formaldehyde-treated samples of maternal blood obtained from a network of 27 US clinical sites in 16 states.


METHODS
Percentage of free fetal DNA in samples of maternal blood.


RESULTS
In the first phase of the study, the mean percentage of free fetal DNA in the untreated samples was 7.7% (range, 0.32%-40%), while the mean percentage of free fetal DNA in the formaldehyde-treated samples was 20.2% (range, 1.6%-40%) (P =.02 for difference). In the second phase, a median of 25% (range, 3.1% to >50%) free fetal DNA was obtained for the 69 formaldehyde-treated maternal blood samples. Approximately 59% of the samples in this study had 25% or greater fetal DNA, and only 16% of the samples had less than 10% fetal DNA. In addition, 27.5% of the samples in this study had 50% or greater fetal DNA.


CONCLUSIONS
Addition of formaldehyde to maternal blood samples, coupled with careful processing protocols, increases the relative percentage of free fetal DNA, providing a foundation for development of noninvasive prenatal diagnostic tests to distinguish fetal DNA from maternal DNA in the maternal circulation.
Ravgen Inc, Columbia, Md 21045, USA. rdhallan@ravgen.com
Ravinder
R
Dhallan
Wei-Chun
WC
Au
Subhendra
S
Mattagajasingh
Sarah
S
Emche
Philip
P
Bayliss
Marian
M
Damewood
Michael
M
Cronin
Victoria
V
Chou
Michelle
M
Mohr
D001800:Blood Specimen Collection / Q000379:methods*; D004247:DNA / Q000097:blood* / Q000302:isolation & purification; D005260:Female; D005333:Fetus; D005557:Formaldehyde; D005820:Genetic Testing; D006801:Humans; D008297:Male; D008431:Maternal-Fetal Exchange; D010949:Plasma; D016133:Polymerase Chain Reaction; D011247:Pregnancy / Q000097:blood*; D011296:Prenatal Diagnosis / Q000379:methods*
D005557:Formaldehyde; D004247:DNA